High level of tumor necrosis alpha and serum interferon gamma as risk factors for progression of vitiligo disease
Keywords:
IFN, TNF, VASI, VIDA, Vitiligo ProgressivityAbstract
Vitiligo is an autoimmune disease that causes melanocyte of dysfunction. Cytokines played an important role in the pathogenesis of vitiligo. Interferon-gamma and TNF-µ were cytokines that induce apoptosis of melanocyte cell. The increase of cytokine levels affects the clinical course of vitiligo. The stable and progressive phase of vitiligo clinically is not easy to predict. Assessment of vitiligo stability could be used to determine treatment options, duration of therapy and prognosis. This study was a cross-sectional observational study which intended to prove high levels of TNF-? and IFN-g serum is a risk factor for vitiligo progression. The demographic, clinical, and laboratory data in active vitiligo subjects (n=30) were compared with stable vitiligo subjects (n=40). The relationship was analyzed with multivariate. Median of the subject age with active vitiligo was 44 years (8~60) and on the subject with stable vitiligo was 45 years (15~66). The most subjects were male (58.5%) and the most common type of vitiligo was non-segmental vitiligo (87.1%). Multivariate analysis showed a high level of TNF-µ serum increased the risk of vitiligo progressivity (Adjusted PR 390.89; CI 95 % 27.98-5460.12 ; p<0,001) and high level of IFN-g serum increased the risk of vitiligo progressivity (Adjusted PR 341.06; CI 95% 33.40-3482.26 ; p<0,001). The high level of TNF-µ and IFN-g serum as a risk factor for progression of vitiligo could be used to assess the activity of vitiligo disease. The further research about the association between TNF-µ and IFN-g to predict the therapeutic response in vitiligo.
Downloads
References
Abreu, A. C. G., Duarte, G. G., Miranda, J. Y. P., Ramos, D. G., Ramos, C. G., & Ramos, M. G. (2015). Immunological parameters associated with vitiligo treatments: a literature review based on clinical studies. Autoimmune Diseases, 2015.
Agarwal, R., Jain, P., Ghosh, M. S., & Parihar, K. S. (2017). Importance of Primary Health Care in the Society. International Journal of Health Sciences (IJHS), 1(1), 6-11.
Ala, Y., Pasha, M. K., Rao, R. N., Komaravalli, P. L., & Jahan, P. (2015). Association of IFN-?: IL-10 cytokine ratio with Nonsegmental Vitiligo pathogenesis. Autoimmune Diseases, 2015.
Alghamdi, K. M., Kumar, A., Taïeb, A., & Ezzedine, K. (2012). Assessment methods for the evaluation of vitiligo. Journal of the European Academy of Dermatology and Venereology, 26(12), 1463-1471.
Aydingoz, et, al. (2015). The combination of tumour necrosis factor??? 308A and interleukin?10? 1082G gene polymorphisms and increased serum levels of related cytokines: susceptibility to vitiligo. Clinical and experimental dermatology, 40(1), 71-77.
Dwivedi, M., Laddha, N. C., & Begum, R. (2013). Correlation of increased MYG1 expression and its promoter polymorphism with disease progression and higher susceptibility in vitiligo patients. Journal of dermatological science, 71(3), 195-202.
Dwivedi, M., Laddha, N. C., Shah, K., Shah, B. J., & Begum, R. (2013). Involvement of interferon-gamma genetic variants and intercellular adhesion molecule-1 in onset and progression of generalized vitiligo. Journal of Interferon & Cytokine Research, 33(11), 646-659.
Ezzedine, K., & Silverberg, N. (2016). A practical approach to the diagnosis and treatment of vitiligo in children. Pediatrics, 138(1), e20154126.
Frisoli, M. L., & Harris, J. E. (2017). Vitiligo: Mechanistic insights lead to novel treatments. Journal of Allergy and Clinical Immunology, 140(3), 654-662.
Glassman, S. J. (2011). Vitiligo, reactive oxygen species and T-cells. Clinical Science, 120(3), 99-120.
Jadali, Z. (2015). IFN-? Promotes Apoptosis of Melanocytes in Vitiligo. Journal of Skin and Stem Cell, 2(4).
Lee, H., Lee, M. H., Lee, D. Y., Kang, H. Y., Kim, K. H., Choi, G. S., ... & Lee, A. Y. (2015). Prevalence of vitiligo and associated comorbidities in Korea. Yonsei medical journal, 56(3), 719-725.
Liu, L. Y., Strassner, J. P., Refat, M. A., Harris, J. E., & King, B. A. (2017). Repigmentation in vitiligo using the Janus kinase inhibitor tofacitinib may require concomitant light exposure. Journal of the American Academy of Dermatology, 77(4), 675-682.
Lopes, C., Trevisani, V. F. M., & Melnik, T. (2016). Efficacy and safety of 308-nm monochromatic excimer lamp versus other phototherapy devices for vitiligo: a systematic review with meta-analysis. American journal of clinical dermatology, 17(1), 23-32.
Lotti, T., Hercogova, J., & Fabrizi, G. (2015). Advances in the treatment options for vitiligo: activated low-dose cytokines-based therapy. Expert opinion on pharmacotherapy, 16(16), 2485-2496.
Malaiya, S., Shrivastava, A., Prasad, G., & Jain, P. (2017). Impact of Medical Education Trend in Community Development. International Journal of Health Sciences (IJHS), 1(1), 23-27.
Rashighi, M., & Harris, J. E. (2015). Interfering with the IFN-?/CXCL10 pathway to develop new targeted treatments for vitiligo. Annals of translational medicine, 3(21).
Sahni, K., & Parsad, D. (2013). Stability in vitiligo: is there a perfect way to predict it?. Journal of cutaneous and aesthetic surgery, 6(2), 75.
Son, J., Kim, M., Jou, I., Park, K. C., & Kang, H. Y. (2014). IFN?? inhibits basal and ??MSH?induced melanogenesis. Pigment cell & melanoma research, 27(2), 201-208.
Webb, K. C., Tung, R., Winterfield, L. S., Gottlieb, A. B., Eby, J. M., Henning, S. W., & Le Poole, I. C. (2015). Tumour necrosis factor?? inhibition can stabilize disease in progressive vitiligo. British Journal of Dermatology, 173(3), 641-650.
Wirawan, I. G. B. (2018). Surya Namaskara Benefits for Physical Health. International Journal of Social Sciences and Humanities (IJSSH), 2(1), 43-55.
Yang, L., Wei, Y., Sun, Y., Shi, W., Yang, J., Zhu, L., & Li, M. (2015). Interferon-gamma inhibits melanogenesis and induces apoptosis in melanocytes: a pivotal role of CD8+ cytotoxic T lymphocytes in vitiligo. Acta dermato-venereologica, 95(6), 664-671.
Published
How to Cite
Issue
Section
Articles published in the International Journal of Health Sciences (IJHS) are available under Creative Commons Attribution Non-Commercial No Derivatives Licence (CC BY-NC-ND 4.0). Authors retain copyright in their work and grant IJHS right of first publication under CC BY-NC-ND 4.0. Users have the right to read, download, copy, distribute, print, search, or link to the full texts of articles in this journal, and to use them for any other lawful purpose.
Articles published in IJHS can be copied, communicated and shared in their published form for non-commercial purposes provided full attribution is given to the author and the journal. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
This copyright notice applies to articles published in IJHS volumes 4 onwards. Please read about the copyright notices for previous volumes under Journal History.
